2009•Bladder CancerRequires access

Beyond BCG: Gemcitabine

Ganesh V. Raj, Guido Dalbagni

Abstract

Currently, recurrence of carcinoma in situ (CIS) after intravesical BCG mandates a radical cystectomy, as BCG-refractory CIS is aggressive with a high propensity for progression. Novel intravesical agents are needed to salvage refractory disease. Gemcitabine is an antimetabolite with proven single agent efficacy against metastatic bladder cancer. In this review, the ability of gemcitabine to treat BCG-refractory CIS is examined in preclinical, phase I and phase II trials. Future studies with intravesical gemcitabine are also examined.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Gemcitabine, Antimetabolite, Refractory (planetary science), Medicine, Cystectomy, Oncology, Bladder cancer, Internal medicine